Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Alexander

Showing results (91-100 of 136) with videos related to

Pageof 14
Sort By:
International Journal of Oncology|November 27, 2010
Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cellsToni Urbanik, Bruno Christian Köhler, Regina Johanna Boger, et al.
Diagnostics (Basel, Switzerland)|May 28, 2022
Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver CirrhosisLeonard Kaps, Lejla Lukac, Maurice Michel, et al.
Sexually Transmitted Diseases|March 10, 2020
A Secondary Mixed Methods Analysis of a Pay-it-Forward Gonorrhea/Chlamydia Testing Program Among Men Who Have Sex With Men in ChinaKatherine T Li, Wenting Huang, Weiming Tang, et al.
BMC Pulmonary Medicine|April 22, 2021
A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CFStephanie Thee, Mirjam Stahl, Rainald Fischer, et al.
Health Science Reports|June 17, 2021
Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goalChristoph Sarrazin, Christoph Boesecke, Solmaz Golsabahi-Broclawski, et al.
Journal of Clinical Gastroenterology|November 16, 2018
Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic EncephalopathyChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
Journal of Hepatology|June 26, 2012
Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in miceToni Urbanik, Regina Johanna Boger, Thomas Longerich, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|September 16, 2022
Management of Hepatic SarcoidosisJanina Sollors, Bernhard Schlevogt, Hartmut J Schmidt, et al.
Journal of Clinical Gastroenterology|February 28, 2009
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisMarcus Alexander Wörns, Arndt Weinmann, Kerstin Pfingst, et al.
Clinical and Translational Gastroenterology|July 29, 2022
Frailty as Tested by the Clinical Frailty Scale Is a Risk Factor for Hepatorenal Syndrome in Patients With Liver CirrhosisEva Maria Schleicher, Wolfgang Maximilian Kremer, Vasiliki Kalampoka, et al.
Pageof 14

Showing results (91-100 of 136) with videos related to

Sort By:
Pageof 14
International Journal of Oncology|November 27, 2010
Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cellsToni Urbanik, Bruno Christian Köhler, Regina Johanna Boger, et al.
Diagnostics (Basel, Switzerland)|May 28, 2022
Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver CirrhosisLeonard Kaps, Lejla Lukac, Maurice Michel, et al.
Sexually Transmitted Diseases|March 10, 2020
A Secondary Mixed Methods Analysis of a Pay-it-Forward Gonorrhea/Chlamydia Testing Program Among Men Who Have Sex With Men in ChinaKatherine T Li, Wenting Huang, Weiming Tang, et al.
BMC Pulmonary Medicine|April 22, 2021
A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CFStephanie Thee, Mirjam Stahl, Rainald Fischer, et al.
Health Science Reports|June 17, 2021
Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goalChristoph Sarrazin, Christoph Boesecke, Solmaz Golsabahi-Broclawski, et al.
Journal of Clinical Gastroenterology|November 16, 2018
Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic EncephalopathyChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
Journal of Hepatology|June 26, 2012
Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in miceToni Urbanik, Regina Johanna Boger, Thomas Longerich, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|September 16, 2022
Management of Hepatic SarcoidosisJanina Sollors, Bernhard Schlevogt, Hartmut J Schmidt, et al.
Journal of Clinical Gastroenterology|February 28, 2009
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisMarcus Alexander Wörns, Arndt Weinmann, Kerstin Pfingst, et al.
Clinical and Translational Gastroenterology|July 29, 2022
Frailty as Tested by the Clinical Frailty Scale Is a Risk Factor for Hepatorenal Syndrome in Patients With Liver CirrhosisEva Maria Schleicher, Wolfgang Maximilian Kremer, Vasiliki Kalampoka, et al.
Pageof 14